Cite
Phase I/II study of 90Y-clivatuzumab tetraxetan (90Y-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results
MLA
John S. Kauh, et al. “Phase I/II Study of 90Y-Clivatuzumab Tetraxetan (90Y-HPAM4) Combined with Gemcitabine (Gem) in Advanced Pancreatic Cancer (APC): Final Results.” Journal of Clinical Oncology, vol. 30, May 2012, p. 4043. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........0495d91ad67daed0e5d7541b5898b525&authtype=sso&custid=ns315887.
APA
John S. Kauh, Seza A. Gulec, David V. Gold, Kenneth Pennington, Tanios Bekaii-Saab, Heather Horne, Michael J. Guarino, Edith P. Mitchell, Allyson J. Ocean, David M. Goldenberg, Gregory M. Springett, Alberto J. Montero, Max Sung, & William A. Wegener. (2012). Phase I/II study of 90Y-clivatuzumab tetraxetan (90Y-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results. Journal of Clinical Oncology, 30, 4043.
Chicago
John S. Kauh, Seza A. Gulec, David V. Gold, Kenneth Pennington, Tanios Bekaii-Saab, Heather Horne, Michael J. Guarino, et al. 2012. “Phase I/II Study of 90Y-Clivatuzumab Tetraxetan (90Y-HPAM4) Combined with Gemcitabine (Gem) in Advanced Pancreatic Cancer (APC): Final Results.” Journal of Clinical Oncology 30 (May): 4043. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........0495d91ad67daed0e5d7541b5898b525&authtype=sso&custid=ns315887.